Study to Evaluate the Drug-drug Interaction Effect of Omeprazole on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants
An Open-label Study to Evaluate the Drug-drug Interaction Effect of Omeprazole, a Proton-pump Inhibitor, on the Pharmacokinetics of AMG 510 in Healthy Subjects
Sponsor: Amgen
This PHASE1 trial investigates Healthy Participants and is currently completed. Amgen leads this study, which shows 6 recorded versions since 2020 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
6 versions recorded-
Apr 2025 — Present [monthly]
Completed PHASE1
-
Mar 2025 — Apr 2025 [monthly]
Completed PHASE1
-
Jan 2025 — Mar 2025 [monthly]
Completed PHASE1
-
Sep 2024 — Jan 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
▶ Show 1 earlier version
-
Nov 2022 — Jul 2024 [monthly]
Completed PHASE1
First recorded
Jan 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Amgen
For direct contact, visit the study record on ClinicalTrials.gov .